Epidermal Growth Factor Receptor Exon 20 Insertion in Early Resected Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study in Taiwan.

IF 1 Q4 Medicine
Ying Shian Chen, Hsu-Kai Huang, Ying-Yi Chen, Yen-Shou Kuo, Kuan Hsun Lin, Cheng-Jung Lin, Tsai-Wang Huang
{"title":"Epidermal Growth Factor Receptor Exon 20 Insertion in Early Resected Non-Small Cell Lung Cancer: A Retrospective, Single-Center Study in Taiwan.","authors":"Ying Shian Chen, Hsu-Kai Huang, Ying-Yi Chen, Yen-Shou Kuo, Kuan Hsun Lin, Cheng-Jung Lin, Tsai-Wang Huang","doi":"10.5090/jcs.25.027","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><i>EGFR</i> exon 20 insertions account for 1% to 10% of <i>EGFR</i> mutations in non-small-cell lung cancer (NSCLC) and are known to confer resistance to traditional tyrosine kinase inhibitors. However, the prognostic significance of these mutations in early-stage resected NSCLC remains unclear. This study assesses outcomes in patients with resected NSCLC harboring <i>EGFR</i> exon 20 insertions, comparing them to patients with common <i>EGFR</i> mutations and those with wild-type <i>EGFR</i>.</p><p><strong>Methods: </strong>We retrospectively reviewed 3,235 patients who underwent resection for NSCLC at Tri-Service Hospital between 2008 and 2021. After excluding cases lacking <i>EGFR</i> testing, incomplete data, or advanced-stage disease, 44 patients with exon 20 insertions were matched to 602 patients with common <i>EGFR</i> mutations and 729 with wild-type <i>EGFR</i>. Clinical characteristics, disease-free survival (DFS), and overall survival (OS) were analyzed using the Kaplan-Meier method, with statistical comparisons performed using the log-rank test. Cox proportional hazards models were used to identify independent prognostic factors.</p><p><strong>Results: </strong>Patients with exon 20 insertions were younger and more frequently presented with stage IA disease. The 5-year DFS was 79% in the exon 20 insertion group, compared to 81% in the common mutation group and 83.9% in the wild-type group. The 5-year OS was 78.5% for exon 20, 91.9% for common mutations, and 91% for wild-type. While no significant differences in DFS or OS were observed between groups, the exon 20 insertion group had a higher incidence of secondary cancers. Multivariable analysis indicated that exon 20 insertion was independently associated with worse OS, but not with DFS.</p><p><strong>Conclusion: </strong><i>EGFR</i> exon 20 insertions do not significantly shorten DFS, but are associated with inferior OS in early-stage resected NSCLC. Given the limited treatment options, the role of adjuvant therapy warrants further investigation.</p>","PeriodicalId":34499,"journal":{"name":"Journal of Chest Surgery","volume":" ","pages":""},"PeriodicalIF":1.0000,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Chest Surgery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5090/jcs.25.027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: EGFR exon 20 insertions account for 1% to 10% of EGFR mutations in non-small-cell lung cancer (NSCLC) and are known to confer resistance to traditional tyrosine kinase inhibitors. However, the prognostic significance of these mutations in early-stage resected NSCLC remains unclear. This study assesses outcomes in patients with resected NSCLC harboring EGFR exon 20 insertions, comparing them to patients with common EGFR mutations and those with wild-type EGFR.

Methods: We retrospectively reviewed 3,235 patients who underwent resection for NSCLC at Tri-Service Hospital between 2008 and 2021. After excluding cases lacking EGFR testing, incomplete data, or advanced-stage disease, 44 patients with exon 20 insertions were matched to 602 patients with common EGFR mutations and 729 with wild-type EGFR. Clinical characteristics, disease-free survival (DFS), and overall survival (OS) were analyzed using the Kaplan-Meier method, with statistical comparisons performed using the log-rank test. Cox proportional hazards models were used to identify independent prognostic factors.

Results: Patients with exon 20 insertions were younger and more frequently presented with stage IA disease. The 5-year DFS was 79% in the exon 20 insertion group, compared to 81% in the common mutation group and 83.9% in the wild-type group. The 5-year OS was 78.5% for exon 20, 91.9% for common mutations, and 91% for wild-type. While no significant differences in DFS or OS were observed between groups, the exon 20 insertion group had a higher incidence of secondary cancers. Multivariable analysis indicated that exon 20 insertion was independently associated with worse OS, but not with DFS.

Conclusion: EGFR exon 20 insertions do not significantly shorten DFS, but are associated with inferior OS in early-stage resected NSCLC. Given the limited treatment options, the role of adjuvant therapy warrants further investigation.

表皮生长因子受体外显子20插入在早期切除的非小细胞肺癌:台湾的回顾性单中心研究。
背景:EGFR外显子20插入占非小细胞肺癌(NSCLC) EGFR突变的1%至10%,并且已知会赋予对传统酪氨酸激酶抑制剂的抗性。然而,这些突变在早期非小细胞肺癌切除术中的预后意义尚不清楚。本研究评估了EGFR外显子20插入的非小细胞肺癌切除患者的预后,并将其与普通EGFR突变患者和野生型EGFR患者进行了比较。方法:我们回顾性分析了2008年至2021年间在三服务医院接受非小细胞肺癌切除术的3235例患者。在排除缺乏EGFR检测、数据不完整或疾病晚期的病例后,44名外显子20插入的患者与602名普通EGFR突变患者和729名野生型EGFR突变患者相匹配。采用Kaplan-Meier法分析临床特征、无病生存期(DFS)和总生存期(OS),采用log-rank检验进行统计学比较。采用Cox比例风险模型确定独立预后因素。结果:外显子20插入的患者更年轻,更常出现IA期疾病。外显子20插入组的5年DFS为79%,而普通突变组为81%,野生型组为83.9%。外显子20的5年OS为78.5%,普通突变为91.9%,野生型为91%。虽然两组间DFS或OS无显著差异,但外显子20插入组继发性癌症发生率较高。多变量分析表明外显子20插入与较差的OS独立相关,但与DFS无关。结论:EGFR外显子20的插入不会显著缩短DFS,但与早期切除的NSCLC的低OS相关。鉴于有限的治疗选择,辅助治疗的作用值得进一步研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Chest Surgery
Journal of Chest Surgery Medicine-Surgery
CiteScore
0.80
自引率
0.00%
发文量
76
审稿时长
7 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信